Emergent BioSolutions to Participate in Investor Conferences
June 02, 2022 08:20 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
May 16, 2022 06:32 ET
|
Emergent BioSolutions
Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
May 12, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions Reports Financial Results For First Quarter 2022
April 28, 2022 16:05 ET
|
Emergent BioSolutions
Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG,...
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
April 08, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions Provides Corporate Governance Update
March 23, 2022 16:05 ET
|
Emergent BioSolutions
Zsolt Harsanyi, Ph.D. Appointed Chairman of the BoardKeith Katkin Appointed to the BoardEliminates Role of Executive ChairmanAppoints New Chairs of Audit, Strategic Operations, and Scientific Review...
Emergent BioSolutions to Participate in Investor Conferences
March 14, 2022 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
March 11, 2022 06:34 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety,...
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
February 24, 2022 16:05 ET
|
Emergent BioSolutions
Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidanceUpdates full year 2022...
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
February 07, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the...